5 research outputs found
Π ΡΠΎΡΡΠΎΡΠ½ΠΈΠΈ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠΈ Π·Π°Π½ΡΡΠΎΡΡΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈ
Ensuring the equal employment opportunities for persons with disabilities is one of the priorities of public support for people with disabilities in Russia. This determines the need for detailed, reliable and timely statistics on the position of persons with disabilities in the labor market. The authors analyzed the content and quality of statistics collected in this area, considering, in particular, the recent methodological, organizational and statistical innovations - inclusion of the questions about disability status in the key population surveys and creation of the Federal Register of Disabled Persons (FRD).The article notes that to date, estimates of the employment rate of persons with disabilities on the basis of administrative data and labor force survey differ, which justifies the need for an additional analysis of the methodology of these indicators. Thus, data of the FRD contains information about all people with disability status in Russia, but information on their employment covers mostly employment in the formal sector. While the population survey data, according to the authors, on the contrary, make it possible to take into account allforms of employΒ¬ment, but face the problem of underestimating of people with disabilities due to the design of the questions used, the reluctance of individuals to declare disability, and due to the fact that some groups of people with disabilities are less likely to be respondents of the surveys. In addition, the administrative data and the labor force survey data differ in the length of the reference period and methodology of calculation of annual indicators.According to the authors analysis, administrative data reflects the number of employed persons with disabilities more objectively, while for detailed characteristics of disabled people position in the labor market population survey data may be used.ΠΠ±Π΅ΡΠΏΠ΅ΡΠ΅Π½ΠΈΠ΅ ΡΠ°Π²Π½ΠΎΠ³ΠΎ Π΄ΠΎΡΡΡΠΏΠ° ΠΈ ΡΠ°Π²Π½ΡΡ
Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠ΅ΠΉ Π΄Π»Ρ Π»ΠΈΡ Ρ ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π½ΠΎΡΡΡΡ Π½Π° ΡΡΠ½ΠΊΠ΅ ΡΡΡΠ΄Π° ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠΎΠ² Π³ΠΎΡΡΠ΄Π°ΡΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² Π ΠΎΡΡΠΈΠΈ. ΠΡΠΎ ΠΎΠΏΡΠ΅Π΄Π΅Π»ΡΠ΅Ρ ΠΏΠΎΡΡΠ΅Π±Π½ΠΎΡΡΡ Π² ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎΠΉ, Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΠΉ ΠΈ ΠΎΠΏΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ ΡΡΠ°ΡΠΈΡΡΠΈΠΊΠ΅ ΠΎ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π° ΡΡΠ½ΠΊΠ΅ ΡΡΡΠ΄Π°. ΠΠ²ΡΠΎΡΡ ΠΏΡΠΎΠ°Π½Π°Π»ΠΈΠ·ΠΈΡΠΎΠ²Π°Π»ΠΈ ΡΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΠΈ ΠΊΠ°ΡΠ΅ΡΡΠ²ΠΎ ΡΠΎΠ±ΠΈΡΠ°Π΅ΠΌΡΡ
ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π΄Π°Π½Π½ΡΡ
Π² ΡΡΠΎΠΉ ΠΎΠ±Π»Π°ΡΡΠΈ, ΡΠ°ΡΡΠΌΠΎΡΡΠ΅Π², Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ, ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΎΠ½Π½ΠΎ-ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π½ΠΎΠ²Π°ΡΠΈΠΈ ΠΏΠΎΡΠ»Π΅Π΄Π½Π΅Π³ΠΎ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ - Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅ Π²ΠΎΠΏΡΠΎΡΠ° ΠΎ Π½Π°Π»ΠΈΡΠΈΠΈ ΡΡΠ°ΡΡΡΠ° ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π° Π² ΠΊΠ»ΡΡΠ΅Π²ΡΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΈ ΡΠΎΠ·Π΄Π°Π½ΠΈΠ΅ Π€Π΅Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅Π΅ΡΡΡΠ° ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² (Π€Π Π).Π ΡΡΠ°ΡΡΠ΅ ΠΎΡΠΌΠ΅ΡΠ°Π΅ΡΡΡ, ΡΡΠΎ ΠΈ Π½Π° ΡΠ΅Π³ΠΎΠ΄Π½ΡΡΠ½ΠΈΠΉ Π΄Π΅Π½Ρ ΠΎΡΠ΅Π½ΠΊΠΈ ΡΡΠΎΠ²Π½Ρ Π·Π°Π½ΡΡΠΎΡΡΠΈ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² ΠΏΠΎ Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠ°ΡΠΈΠ²Π½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ ΠΈ ΠΏΠΎ Π΄Π°Π½Π½ΡΠΌ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π±ΠΎΡΠ΅ΠΉ ΡΠΈΠ»Ρ ΡΠ°ΡΡ
ΠΎΠ΄ΡΡΡΡ, ΡΡΠΎ ΠΎΠ±ΠΎΡΠ½ΠΎΠ²ΡΠ²Π°Π΅Ρ Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠΎΡΡΡ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΡ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΠΎΠ³ΠΎ Π°Π½Π°Π»ΠΈΠ·Π° ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΠΈ ΡΡΠΈΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ. Π’Π°ΠΊ, Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠ°ΡΠΈΠ²Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅ Π€Π Π ΡΠΎΠ΄Π΅ΡΠΆΠ°Ρ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΎΠ±ΠΎ Π²ΡΠ΅Ρ
Π»ΠΈΡΠ°Ρ
ΡΠΎ ΡΡΠ°ΡΡΡΠΎΠΌ ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π°, ΠΎΠ΄Π½Π°ΠΊΠΎ Π·Π°Π½ΡΡΠΎΡΡΡ Π² ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²ΠΈΠΈ Ρ ΡΡΠΈΠΌ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠΌ ΠΎΠ³ΡΠ°Π½ΠΈΡΠΈΠ²Π°Π΅ΡΡΡ ΠΏΡΠ΅ΠΈΠΌΡΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎ ΡΠΎΡΠΌΠ°Π»ΡΠ½ΡΠΌ ΡΠ΅ΠΊΡΠΎΡΠΎΠΌ ΡΠΊΠΎΠ½ΠΎΠΌΠΈΠΊΠΈ. ΠΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ, Π½Π°ΠΏΡΠΎΡΠΈΠ², ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ, ΠΏΠΎ ΠΌΠ½Π΅Π½ΠΈΡ Π°Π²ΡΠΎΡΠΎΠ², ΡΡΠ΅ΡΡΡ Π²ΡΠ΅ ΡΠΎΡΠΌΡ Π·Π°Π½ΡΡΠΎΡΡΠΈ, Π½ΠΎ Π΄Π»Ρ Π½ΠΈΡ
, ΠΊΠ°ΠΊ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ² ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ, Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠ½Π° ΠΏΡΠΎΠ±Π»Π΅ΠΌΠ° Π½Π΅Π΄ΠΎΡΡΠ΅ΡΠ° ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² ΠΈΠ·-Π·Π° Π΄ΠΈΠ·Π°ΠΉΠ½Π° ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π²ΠΎΠΏΡΠΎΡΠΎΠ², Π½Π΅ΠΆΠ΅Π»Π°Π½ΠΈΡ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ
Π»ΠΈΡ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°Π΅ΠΌΠΎΠΉ ΡΠ°ΡΡΠΈ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ Π·Π°ΡΠ²Π»ΡΡΡ ΠΎΠ± ΠΈΠ½Π²Π°Π»ΠΈΠ΄Π½ΠΎΡΡΠΈ, ΠΌΠ΅Π½ΡΡΠ΅ΠΉ Π²Π΅ΡΠΎΡΡΠ½ΠΎΡΡΠΈ ΠΏΠΎΠΏΠ°Π΄Π°Π½ΠΈΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ
Π³ΡΡΠΏΠΏ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π² ΡΠΈΡΠ»ΠΎ ΡΠ΅ΡΠΏΠΎΠ½Π΄Π΅Π½ΡΠΎΠ². ΠΡΠΎΠΌΠ΅ ΡΠΎΠ³ΠΎ, Π² ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΈΡ
Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡΡ
Π² Π²ΠΈΠ΄Π΅ Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ ΠΎΡΡΠ΅ΡΠ½ΠΎΡΡΠΈ ΠΈ Π² ΡΠΎΡΠΌΠ°ΡΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΡΠ°Π·Π»ΠΈΡΠ°ΡΡΡΡ Π΄Π»ΠΈΠ½Π° ΠΎΠ±ΡΠ»Π΅Π΄ΡΠ΅ΠΌΠΎΠ³ΠΎ ΠΏΠ΅ΡΠΈΠΎΠ΄Π° ΠΈ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ»ΠΎΠ³ΠΈΡ ΡΠΎΡΠΌΠΈΡΠΎΠ²Π°Π½ΠΈΡ Π³ΠΎΠ΄ΠΎΠ²ΡΡ
ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Π΅ΠΉ.ΠΡΠ³ΡΠΌΠ΅Π½ΡΠΈΡΡΠ΅ΡΡΡ ΠΎΡΠ΅Π½ΠΎΡΠ½Π°Ρ ΠΏΠΎΠ·ΠΈΡΠΈΡ Π°Π²ΡΠΎΡΠΎΠ², Π·Π°ΠΊΠ»ΡΡΠ°ΡΡΠ°ΡΡΡ Π² ΡΠΎΠΌ, ΡΡΠΎ ΡΠΈΡΠ»Π΅Π½Π½ΠΎΡΡΡ Π·Π°Π½ΡΡΡΡ
ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΎΠ±ΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎ ΠΎΡΡΠ°ΠΆΠ°ΡΡ Π°Π΄ΠΌΠΈΠ½ΠΈΡΡΡΠ°ΡΠΈΠ²Π½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅, Π² ΡΠΎ Π²ΡΠ΅ΠΌΡ ΠΊΠ°ΠΊ Π΄Π»Ρ Ρ
Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠΈ ΠΏΠΎΠ»ΠΎΠΆΠ΅Π½ΠΈΡ ΠΈΠ½Π²Π°Π»ΠΈΠ΄ΠΎΠ² Π½Π° ΡΡΠ½ΠΊΠ΅ ΡΡΡΠ΄Π° ΡΠ΅Π»Π΅ΡΠΎΠΎΠ±ΡΠ°Π·Π½ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°ΡΡ Π΄Π°Π½Π½ΡΠ΅ ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ
ΠΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΡΠ°ΡΡΠ΅ΡΠ° ΡΡΠ΅Π΄Π½Π΅ΠΌΠ΅ΡΡΡΠ½ΠΎΠΉ Π·Π°ΡΠ°Π±ΠΎΡΠ½ΠΎΠΉ ΠΏΠ»Π°ΡΡ Π½Π°Π΅ΠΌΠ½ΡΡ ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠΎΠ²
This article focuses on the explanations of changes in official methodology and new information sources used to calculate the average monthly accrued wages of hired workers (employees) in organizations, individual entrepreneurs and individuals (average monthly income from employment).Based on assessments of representativeness of the Sample Statistical Survey of Income (SSSI) by Russian regions, the authors investigate the possibility of abandoning the conditional Β«spreading coefficientΒ» used in the official method of calculating earnings and switching to the direct use of the results of SSSI of hired workers. The article suggests clarifying the composition of categories of employees in order to make fuller use of statistical reporting data of organizations as the most reliable information source.The changes in the official method of calculation of the employees' earnings, which were discussed in the article, are aimed at increasing the accuracy and reliability of the assessment of this indicator for Russia and Russian regions.Π‘ΡΠ°ΡΡΡ ΠΏΠΎΡΠ²ΡΡΠ΅Π½Π° ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½ΠΈΡ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π°Π»Π³ΠΎΡΠΈΡΠΌΠΎΠ² ΠΈ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΡΡ
ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠΎΠ², ΠΈΡΠΏΠΎΠ»ΡΠ·ΡΠ΅ΠΌΡΡ
Π΄Π»Ρ ΡΠ°ΡΡΠ΅ΡΠ° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΡΡΠ΅Π΄Π½Π΅ΠΌΠ΅ΡΡΡΠ½ΠΎΠΉ Π½Π°ΡΠΈΡΠ»Π΅Π½Π½ΠΎΠΉ Π·Π°ΡΠ°Π±ΠΎΡΠ½ΠΎΠΉ ΠΏΠ»Π°ΡΡ Π½Π°Π΅ΠΌΠ½ΡΡ
ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠΎΠ² Π² ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡΡ
, Ρ ΠΈΠ½Π΄ΠΈΠ²ΠΈΠ΄ΡΠ°Π»ΡΠ½ΡΡ
ΠΏΡΠ΅Π΄ΠΏΡΠΈΠ½ΠΈΠΌΠ°ΡΠ΅Π»Π΅ΠΉ ΠΈΒ ΡΠΈΠ·ΠΈΡΠ΅ΡΠΊΠΈΡ
Π»ΠΈΡ (ΡΡΠ΅Π΄Π½Π΅ΠΌΠ΅ΡΡΡΠ½ΠΎΠ³ΠΎ Π΄ΠΎΡ
ΠΎΠ΄Π° ΠΎΡ ΡΡΡΠ΄ΠΎΠ²ΠΎΠΉ Π΄Π΅ΡΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ). ΠΠ° ΠΎΡΠ½ΠΎΠ²Π΅ ΠΎΡΠ΅Π½ΠΎΠΊ ΡΠ΅ΠΏΡΠ΅Π·Π΅Π½ΡΠ°ΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΡΠ±ΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π΄ΠΎΡ
ΠΎΠ΄ΠΎΠ² Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΏΠΎΒ ΡΡΠ±ΡΠ΅ΠΊΡΠ°ΠΌ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ Π°Π²ΡΠΎΡΡ ΠΈΡΡΠ»Π΅Π΄ΡΡΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΡ ΠΎΡΠΊΠ°Π·Π° ΠΎΡ ΡΡΠ»ΠΎΠ²Π½ΠΎΠ³ΠΎ Β«ΠΊΠΎΡΡΡΠΈΡΠΈΠ΅Π½ΡΠ° ΡΠ°ΡΠΏΡΠΎΡΡΡΠ°Π½Π΅Π½ΠΈΡΒ», ΠΏΡΠΈΠΌΠ΅Π½ΡΠ΅ΠΌΠΎΠ³ΠΎ Π² ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠ΅ ΡΠ°ΡΡΠ΅ΡΠ° Π·Π°ΡΠ°Π±ΠΎΡΠ½ΠΎΠΉ ΠΏΠ»Π°ΡΡ, ΠΈ ΠΏΠ΅ΡΠ΅Ρ
ΠΎΠ΄Π° Π½Π° Π½Π΅ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²Π΅Π½Π½ΠΎΠ΅ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠΎΠ² Π²ΡΠ±ΠΎΡΠΎΡΠ½ΠΎΠ³ΠΎ Π½Π°Π±Π»ΡΠ΄Π΅Π½ΠΈΡ Π΄ΠΎΡ
ΠΎΠ΄ΠΎΠ² Π½Π°ΡΠ΅Π»Π΅Π½ΠΈΡ ΠΏΠΎ Π½Π°Π΅ΠΌΠ½ΡΠΌ ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠ°ΠΌ. Π ΡΡΠ°ΡΡΠ΅ ΠΏΡΠ΅Π΄Π»ΠΎΠΆΠ΅Π½ΠΎ ΡΡΠΎΡΠ½Π΅Π½ΠΈΠ΅ ΡΠΎΡΡΠ°Π²Π° ΠΊΠ°ΡΠ΅Π³ΠΎΡΠΈΠΉ Π½Π°Π΅ΠΌΠ½ΡΡ
ΡΠ°Π±ΠΎΡΠ½ΠΈΠΊΠΎΠ² Ρ ΡΠ΅Π»ΡΡ Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ»Π½ΠΎΠ³ΠΎ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΡ Π΄Π°Π½Π½ΡΡ
ΡΡΠ°ΡΠΈΡΡΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΎΡΡΠ΅ΡΠ½ΠΎΡΡΠΈ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΉ ΠΊΠ°ΠΊ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ Π½Π°Π΄Π΅ΠΆΠ½ΠΎΠ³ΠΎ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΎΠ½Π½ΠΎΠ³ΠΎ ΠΈΡΡΠΎΡΠ½ΠΈΠΊΠ°. ΠΡΠ³ΡΠΌΠ΅Π½ΡΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π² ΡΡΠ°ΡΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΎΡΠΈΡΠΈΠ°Π»ΡΠ½ΠΎΠΉΠΌΠ΅ΡΠΎΠ΄ΠΈΠΊΠΈ ΡΠ°ΡΡΠ΅ΡΠ° ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ Π·Π°ΡΠ°Π±ΠΎΡΠ½ΠΎΠΉ ΠΏΠ»Π°ΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½Ρ Π½Π° ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΠ½ΠΎΡΡΠΈ ΠΈ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΠΎΡΡΠΈ ΠΎΡΠ΅Π½ΠΊΠΈ Π΄Π°Π½Π½ΠΎΠ³ΠΎ ΠΏΠΎΠΊΠ°Π·Π°ΡΠ΅Π»Ρ ΠΏΠΎ Π ΠΎΡΡΠΈΠΈ ΠΈ ΡΡΠ±ΡΠ΅ΠΊΡΠ°ΠΌ Π ΠΎΡΡΠΈΠΉΡΠΊΠΎΠΉΒ Π€Π΅Π΄Π΅ΡΠ°ΡΠΈΠΈ
Effects of CYP2C19*2 polymorphisms on the efficacy and safety of phenazepam in patients with anxiety disorder and comorbid alcohol use disorder
Β© 2020 Future Science Group.Introduction: Phenazepam therapy can often be ineffective and some patients develop dose-related adverse drug reactions. Aim. The purpose of this research was to study the effect of the CYP2C19*2 (681G>A,
rs4244285) in patients with anxiety disorders and alcohol dependence taking phenazepam therapy. Materials & methods: Patients (175 males, average age: 37.16 Β± 7.84 years) received phenazepam in tablet form
for 5 days. Genotyping was performed by real-time polymerase chain reaction. Results: The statistically significant differences in the UKU Side-Effect Rating Scale scores on the fifth day of therapy: (CYP2C19*1/*1)
2.00 [1.00; 2.00), (CYP2C19*1/*2) 7.00 (7.00; 7.00), (CYP2C19*2/*2) 9.00 (8.00; 9.00), p < 0.001. Conclusion:
This study demonstrated the different efficacy and safety of phenazepam in patients with different genotypes of CYP2C19*2.This work was supported by the project titled βFundamental research and exploratory research in priority areas of researchβ of the Russian Science Foundation and by the Presidentβs Grant of state support for the young scientists (project MK-2460.2018.7).info:eu-repo/semantics/publishedVersio
Rivaroxaban with or without aspirin in stable cardiovascular disease
BACKGROUND: We evaluated whether rivaroxaban alone or in combination with aspirin would be more effective than aspirin alone for secondary cardiovascular prevention. METHODS: In this double-blind trial, we randomly assigned 27,395 participants with stable atherosclerotic vascular disease to receive rivaroxaban (2.5 mg twice daily) plus aspirin (100 mg once daily), rivaroxaban (5 mg twice daily), or aspirin (100 mg once daily). The primary outcome was a composite of cardiovascular death, stroke, or myocardial infarction. The study was stopped for superiority of the rivaroxaban-plus-aspirin group after a mean follow-up of 23 months. RESULTS: The primary outcome occurred in fewer patients in the rivaroxaban-plus-aspirin group than in the aspirin-alone group (379 patients [4.1%] vs. 496 patients [5.4%]; hazard ratio, 0.76; 95% confidence interval [CI], 0.66 to 0.86; P<0.001; z=β4.126), but major bleeding events occurred in more patients in the rivaroxaban-plus-aspirin group (288 patients [3.1%] vs. 170 patients [1.9%]; hazard ratio, 1.70; 95% CI, 1.40 to 2.05; P<0.001). There was no significant difference in intracranial or fatal bleeding between these two groups. There were 313 deaths (3.4%) in the rivaroxaban-plus-aspirin group as compared with 378 (4.1%) in the aspirin-alone group (hazard ratio, 0.82; 95% CI, 0.71 to 0.96; P=0.01; threshold P value for significance, 0.0025). The primary outcome did not occur in significantly fewer patients in the rivaroxaban-alone group than in the aspirin-alone group, but major bleeding events occurred in more patients in the rivaroxaban-alone group. CONCLUSIONS: Among patients with stable atherosclerotic vascular disease, those assigned to rivaroxaban (2.5 mg twice daily) plus aspirin had better cardiovascular outcomes and more major bleeding events than those assigned to aspirin alone. Rivaroxaban (5 mg twice daily) alone did not result in better cardiovascular outcomes than aspirin alone and resulted in more major bleeding events